TESARO Announces Data Presentations at ESMO 2018 Congress
October 20, 2018 01:30 ET
|
TESARO, Inc.
Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancerPRIMA safety data for individualized niraparib dose regimen...
TESARO to Announce Third-Quarter 2018 Financial Results on November 1, 2018
October 18, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO) will announce third-quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial...
TESARO Announces Data Presentations at the ESMO 2018 Congress
October 09, 2018 08:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from six abstracts will be presented at the...
TESARO Announces Data Presentations at the SITC 2018 Annual Meeting
October 01, 2018 18:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced that data from a total of five abstracts will be...
TESARO Announces Participation at Two Investor Conferences
September 19, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
TESARO Announces Expansion to Second Stage of JASPER Trial of ZEJULA® in Combination With TSR-042 in Non-Small Cell Lung Cancer
September 04, 2018 16:15 ET
|
TESARO, Inc.
All evaluable patients experienced tumor shrinkageProtocol defined response criteria achieved and trial expansion ongoing WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:...
TESARO Announces Participation at Three Investor Conferences
August 27, 2018 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor...
TESARO Announces Second-Quarter 2018 Operating Results
August 02, 2018 16:05 ET
|
TESARO, Inc.
ZEJULA® Q2 net sales totaled $54 million compared to $26 million for Q2 2017QUADRA sNDA submission planned for Q4 2018PRIMA Phase 3 ZEJULA monotherapy trial in first-line ovarian cancer regardless of...
TESARO to Announce Second-Quarter 2018 Financial Results on August 2, 2018
July 20, 2018 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce second-quarter 2018 financial results on Thursday, August 2, 2018, after the close of the U.S. financial...
TESARO Partners With the Pan-Mass Challenge for 2018 Ride Benefiting Dana-Farber Cancer Institute
July 02, 2018 09:00 ET
|
TESARO, Inc.
WALTHAM, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce a new partnership supporting the Pan-Mass Challenge...